Retraction: Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma
Author: EMJ
Citation: EMJ Oncol. 2026. https://doi.org/10.33590/emjoncol/0XL982SG
Original publication1
Astellas Pharma Ltd. requested removal of this sponsored material because the prescribing information included with it is no longer current.
Reference
1. Ellis N. Sponsored Content: Optimising ▼Enfortumab Vedotin + Pembrolizumab in Comorbid Patients with Unresectable or Metastatic Urothelial Carcinoma.
EMJ Oncol. 2025;13[Suppl 4]:2-14.
